MovDisordV3, PascalFrancis, Corpus, bibRecord, 002966

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

Identifieur interne : 002966 ( PascalFrancis/Corpus ); précédent : 002965; suivant : 002967

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

Auteurs : O. Rascol ; I. Arnulf ; H. Peyro-Saint Paul ; C. Brefel-Courbon ; M. Vidailhet ; C. Thalamas ; A. M. Bonnet ; S. Descombes ; B. Bejjani ; N. Fabre ; J. L. Montastruc ; Y. Agid

Source :

Movement disorders [ 0885-3185 ] ; 2001.

RBID : Pascal:01-0429759

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dyskinésie, Idazoxan, Antagoniste, Récepteur α2-adrénergique, Chimiothérapie, Traitement, Homme, Essai clinique phase II.

English descriptors

KwdEn :
- Antagonist, Chemotherapy, Dyskinesia, Human, Idazoxan, Parkinson disease, Phase II trial, Treatment, α2-Adrenergic receptor.

Abstract

Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopa-therapy. Preclinical data in the 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) monkey suggest that alpha-2 antagonists may reduce dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. We assessed, in a pilot randomised placebo-controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha-2 antagonist, on motor parkinsonian disability and L-DOPA-induced dyskinesia following an acute oral challenge of L-DOPA in 18 patients with Parkinson's disease. The severity of L-DOPA-induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L-DOPA. These results suggest that blocking alpha-2 receptors in patients with Parkinson's disease might improve L-DOPA-induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long-term management of dys-kinetic patients with Parkinson's disease.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 16`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease`
A11	`01`	`1`		`@1 RASCOL (O.)`
A11	`02`	`1`		`@1 ARNULF (I.)`
A11	`03`	`1`		`@1 PAUL (H. Peyro-Saint)`
A11	`04`	`1`		`@1 BREFEL-COURBON (C.)`
A11	`05`	`1`		`@1 VIDAILHET (M.)`
A11	`06`	`1`		`@1 THALAMAS (C.)`
A11	`07`	`1`		`@1 BONNET (A. M.)`
A11	`08`	`1`		`@1 DESCOMBES (S.)`
A11	`09`	`1`		`@1 BEJJANI (B.)`
A11	`10`	`1`		`@1 FABRE (N.)`
A11	`11`	`1`		`@1 MONTASTRUC (J. L.)`
A11	`12`	`1`		`@1 AGID (Y.)`
A14	`01`			`@1 Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital @2 Toulouse @3 FRA @Z 1 aut. @Z 4 aut. @Z 6 aut. @Z 8 aut. @Z 10 aut. @Z 11 aut.`
A14	`02`			`@1 Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere @2 Paris @3 FRA @Z 2 aut. @Z 5 aut. @Z 7 aut. @Z 9 aut. @Z 12 aut.`
A14	`03`			`@1 Institut de recherche Pierre Fabre @2 Boulogne @3 FRA @Z 3 aut.`
A20				`@1 708-713`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000097121190170`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 38 ref.`
A47	`01`	`1`		`@0 01-0429759`
A60				`@1 P @3 EC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopa-therapy. Preclinical data in the 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) monkey suggest that alpha-2 antagonists may reduce dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. We assessed, in a pilot randomised placebo-controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha-2 antagonist, on motor parkinsonian disability and L-DOPA-induced dyskinesia following an acute oral challenge of L-DOPA in 18 patients with Parkinson's disease. The severity of L-DOPA-induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L-DOPA. These results suggest that blocking alpha-2 receptors in patients with Parkinson's disease might improve L-DOPA-induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long-term management of dys-kinetic patients with Parkinson's disease.
C02	`01`	`X`		`@0 002B17G`
C02	`02`	`X`		`@0 002B02B09A`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Dyskinésie @5 04`
C03	`02`	`X`	`ENG`	`@0 Dyskinesia @5 04`
C03	`02`	`X`	`SPA`	`@0 Disquinesia @5 04`
C03	`03`	`X`	`FRE`	`@0 Idazoxan @2 NK @2 FR @5 07`
C03	`03`	`X`	`ENG`	`@0 Idazoxan @2 NK @2 FR @5 07`
C03	`03`	`X`	`SPA`	`@0 Idazoxano @2 NK @2 FR @5 07`
C03	`04`	`X`	`FRE`	`@0 Antagoniste @5 08`
C03	`04`	`X`	`ENG`	`@0 Antagonist @5 08`
C03	`04`	`X`	`SPA`	`@0 Antagonista @5 08`
C03	`05`	`X`	`FRE`	`@0 Récepteur α2-adrénergique @5 09`
C03	`05`	`X`	`ENG`	`@0 α2-Adrenergic receptor @5 09 @6 «α2-»Adrenergic receptor`
C03	`05`	`X`	`SPA`	`@0 Receptor α2-adrenérgico @5 09`
C03	`06`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`06`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`06`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`08`	`X`	`FRE`	`@0 Homme @5 20`
C03	`08`	`X`	`ENG`	`@0 Human @5 20`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`09`	`X`	`FRE`	`@0 Essai clinique phase II @5 23`
C03	`09`	`X`	`ENG`	`@0 Phase II trial @5 23`
C03	`09`	`X`	`SPA`	`@0 Ensayo clínico fase II @5 23`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 46`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 46`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 46`
C07	`07`	`X`	`FRE`	`@0 Mouvement involontaire @5 47`
C07	`07`	`X`	`ENG`	`@0 Involuntary movement @5 47`
C07	`07`	`X`	`SPA`	`@0 Movimiento involuntario @5 47`
N21				`@1 302`

Format Inist (serveur)

NO :	PASCAL 01-0429759 INIST
ET :	Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
AU :	RASCOL (O.); ARNULF (I.); PAUL (H. Peyro-Saint); BREFEL-COURBON (C.); VIDAILHET (M.); THALAMAS (C.); BONNET (A. M.); DESCOMBES (S.); BEJJANI (B.); FABRE (N.); MONTASTRUC (J. L.); AGID (Y.)
AF :	Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital/Toulouse/France (1 aut., 4 aut., 6 aut., 8 aut., 10 aut., 11 aut.); Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere/Paris/France (2 aut., 5 aut., 7 aut., 9 aut., 12 aut.); Institut de recherche Pierre Fabre/Boulogne/France (3 aut.)
DT :	Publication en série; Etude de cas, cas et faits cliniques; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2001; Vol. 16; No. 4; Pp. 708-713; Bibl. 38 ref.
LA :	Anglais
EA :	Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopa-therapy. Preclinical data in the 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) monkey suggest that alpha-2 antagonists may reduce dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. We assessed, in a pilot randomised placebo-controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha-2 antagonist, on motor parkinsonian disability and L-DOPA-induced dyskinesia following an acute oral challenge of L-DOPA in 18 patients with Parkinson's disease. The severity of L-DOPA-induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L-DOPA. These results suggest that blocking alpha-2 receptors in patients with Parkinson's disease might improve L-DOPA-induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long-term management of dys-kinetic patients with Parkinson's disease.
CC :	002B17G; 002B02B09A
FD :	Parkinson maladie; Dyskinésie; Idazoxan; Antagoniste; Récepteur α2-adrénergique; Chimiothérapie; Traitement; Homme; Essai clinique phase II
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire
ED :	Parkinson disease; Dyskinesia; Idazoxan; Antagonist; α2-Adrenergic receptor; Chemotherapy; Treatment; Human; Phase II trial
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement
SD :	Parkinson enfermedad; Disquinesia; Idazoxano; Antagonista; Receptor α2-adrenérgico; Quimioterapia; Tratamiento; Hombre; Ensayo clínico fase II
LO :	INIST-20953.354000097121190170
ID :	01-0429759

Links to Exploration step

Pascal:01-0429759

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I." last="Arnulf">I. Arnulf</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Paul, H Peyro Saint" sort="Paul, H Peyro Saint" uniqKey="Paul H" first="H. Peyro-Saint" last="Paul">H. Peyro-Saint Paul</name>
<affiliation><inist:fA14 i1="03"><s1>Institut de recherche Pierre Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Descombes, S" sort="Descombes, S" uniqKey="Descombes S" first="S." last="Descombes">S. Descombes</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bejjani, B" sort="Bejjani, B" uniqKey="Bejjani B" first="B." last="Bejjani">B. Bejjani</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0429759</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0429759 INIST</idno>
<idno type="RBID">Pascal:01-0429759</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002966</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I." last="Arnulf">I. Arnulf</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Paul, H Peyro Saint" sort="Paul, H Peyro Saint" uniqKey="Paul H" first="H. Peyro-Saint" last="Paul">H. Peyro-Saint Paul</name>
<affiliation><inist:fA14 i1="03"><s1>Institut de recherche Pierre Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Descombes, S" sort="Descombes, S" uniqKey="Descombes S" first="S." last="Descombes">S. Descombes</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bejjani, B" sort="Bejjani, B" uniqKey="Bejjani B" first="B." last="Bejjani">B. Bejjani</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antagonist</term>
<term>Chemotherapy</term>
<term>Dyskinesia</term>
<term>Human</term>
<term>Idazoxan</term>
<term>Parkinson disease</term>
<term>Phase II trial</term>
<term>Treatment</term>
<term>α2-Adrenergic receptor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Idazoxan</term>
<term>Antagoniste</term>
<term>Récepteur α2-adrénergique</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Essai clinique phase II</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopa-therapy. Preclinical data in the 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) monkey suggest that alpha-2 antagonists may reduce dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. We assessed, in a pilot randomised placebo-controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha-2 antagonist, on motor parkinsonian disability and L-DOPA-induced dyskinesia following an acute oral challenge of L-DOPA in 18 patients with Parkinson's disease. The severity of L-DOPA-induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L-DOPA. These results suggest that blocking alpha-2 receptors in patients with Parkinson's disease might improve L-DOPA-induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long-term management of dys-kinetic patients with Parkinson's disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RASCOL (O.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ARNULF (I.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PAUL (H. Peyro-Saint)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BREFEL-COURBON (C.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>VIDAILHET (M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>THALAMAS (C.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BONNET (A. M.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>DESCOMBES (S.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>BEJJANI (B.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>FABRE (N.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>MONTASTRUC (J. L.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>AGID (Y.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Institut de recherche Pierre Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>708-713</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000097121190170</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>38 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0429759</s0>
</fA47>
<fA60><s1>P</s1>
<s3>EC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopa-therapy. Preclinical data in the 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) monkey suggest that alpha-2 antagonists may reduce dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. We assessed, in a pilot randomised placebo-controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha-2 antagonist, on motor parkinsonian disability and L-DOPA-induced dyskinesia following an acute oral challenge of L-DOPA in 18 patients with Parkinson's disease. The severity of L-DOPA-induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L-DOPA. These results suggest that blocking alpha-2 receptors in patients with Parkinson's disease might improve L-DOPA-induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long-term management of dys-kinetic patients with Parkinson's disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B09A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Idazoxan</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Idazoxan</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Idazoxano</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Récepteur α2-adrénergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>α2-Adrenergic receptor</s0>
<s5>09</s5>
<s6>«α2-»Adrenergic receptor</s6>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Receptor α2-adrenérgico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Essai clinique phase II</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Phase II trial</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Ensayo clínico fase II</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>46</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>47</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>47</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>47</s5>
</fC07>
<fN21><s1>302</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 01-0429759 INIST</NO>
<ET>Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease</ET>
<AU>RASCOL (O.); ARNULF (I.); PAUL (H. Peyro-Saint); BREFEL-COURBON (C.); VIDAILHET (M.); THALAMAS (C.); BONNET (A. M.); DESCOMBES (S.); BEJJANI (B.); FABRE (N.); MONTASTRUC (J. L.); AGID (Y.)</AU>
<AF>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital/Toulouse/France (1 aut., 4 aut., 6 aut., 8 aut., 10 aut., 11 aut.); Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie-Salpetriere/Paris/France (2 aut., 5 aut., 7 aut., 9 aut., 12 aut.); Institut de recherche Pierre Fabre/Boulogne/France (3 aut.)</AF>
<DT>Publication en série; Etude de cas, cas et faits cliniques; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2001; Vol. 16; No. 4; Pp. 708-713; Bibl. 38 ref.</SO>
<LA>Anglais</LA>
<EA>Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopa-therapy. Preclinical data in the 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) monkey suggest that alpha-2 antagonists may reduce dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. We assessed, in a pilot randomised placebo-controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha-2 antagonist, on motor parkinsonian disability and L-DOPA-induced dyskinesia following an acute oral challenge of L-DOPA in 18 patients with Parkinson's disease. The severity of L-DOPA-induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L-DOPA. These results suggest that blocking alpha-2 receptors in patients with Parkinson's disease might improve L-DOPA-induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long-term management of dys-kinetic patients with Parkinson's disease.</EA>
<CC>002B17G; 002B02B09A</CC>
<FD>Parkinson maladie; Dyskinésie; Idazoxan; Antagoniste; Récepteur α2-adrénergique; Chimiothérapie; Traitement; Homme; Essai clinique phase II</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire</FG>
<ED>Parkinson disease; Dyskinesia; Idazoxan; Antagonist; α2-Adrenergic receptor; Chemotherapy; Treatment; Human; Phase II trial</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement</EG>
<SD>Parkinson enfermedad; Disquinesia; Idazoxano; Antagonista; Receptor α2-adrenérgico; Quimioterapia; Tratamiento; Hombre; Ensayo clínico fase II</SD>
<LO>INIST-20953.354000097121190170</LO>
<ID>01-0429759</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002966 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002966 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:01-0429759
   |texte=   Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri